Skip to main content

Dacarbazine Disease Interactions

There are 4 disease interactions with dacarbazine.

Major

Antineoplastics (applies to dacarbazine) infections

Major Potential Hazard, High plausibility. Applicable conditions: Infection - Bacterial/Fungal/Protozoal/Viral

Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression. The use of these drugs may be contraindicated in patients with known infectious diseases. All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy. Close clinical monitoring of hematopoietic function is recommended.

Switch to professional interaction data

Major

Dacarbazine (applies to dacarbazine) hepatic dysfunction

Major Potential Hazard, Low plausibility. Applicable conditions: Liver Disease

The pharmacokinetic disposition of dacarbazine may be altered in patients with hepatic impairment. Hepatotoxicity, including hepatic vein thrombosis and hepatocellular necrosis, have been reported. Patients should be instructed to immediately report any sign or symptoms of liver dysfunction such as jaundice, dark urine, right upper quadrant pain, or anorexia. Therapy with dacarbazine should be administered cautiously in patients with or predisposed to compromised hepatic function.

Switch to professional interaction data

Major

Dacarbazine (applies to dacarbazine) myelosuppression

Major Potential Hazard, High plausibility. Applicable conditions: Fever, Bone Marrow Depression/Low Blood Counts, Bleeding

Dacarbazine is myelosuppressive, primarily affecting leukocytes and thrombocytes, although anemia occasionally occurs. Deaths due to myelosuppression have been reported. Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding. Therapy with dacarbazine should be withheld or extreme caution exercised when administered in patients whose bone marrow reserve may be severely depressed. Close clinical monitoring of hematopoietic function is recommended.

Switch to professional interaction data

Moderate

Dacarbazine (applies to dacarbazine) renal dysfunction

Moderate Potential Hazard, Moderate plausibility.

Dacarbazine is partially eliminated by the kidney via renal tubular secretion. Approximately 40% of dacarbazine is eliminated unchanged in the urine. The half-life of dacarbazine may be increased in patients with renal impairment. Rare reports of unspecified, severe renal toxicity has been noted. Therapy with dacarbazine should be administered cautiously to patients with compromised renal function. Clinical monitoring of renal function is recommended.

Switch to professional interaction data

Dacarbazine drug interactions

There are 265 drug interactions with dacarbazine.

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer